Sygnature Discovery has made two key appointments, Dr Allan Jordan and Ms Louisa Jordison.
Ms Jordison joins the independent integrated drug discovery and pre-clinical services provider in the newly-created position of Director of Strategic Planning. She will play a key role in the company’s ambitious planning, growth and capital projects activities. Ms Jordison brings with her a wealth of experience in senior level corporate finance from companies including Experian, Deloitte and KPMG.
Dr Jordan joins as Director of Oncology Drug Discovery. In this new role his primary focus will be to augment Sygnature’s existing oncology drug discovery capabilities and cellular biology.
He joins Sygnature from Cancer Research UK, where he worked for the past decade. A very well-known and respected figure in the global oncology research sector, his appointment plays a key part in Sygnature’s continuous strengthening of their world leading expertise in their key therapeutic areas. In addition to oncology, these are neuroscience and immunology.
Sygnature Discovery’s CEO, Dr Simon Hirst, said: “Louisa’s and Allan’s appointments mark a further step in the development of Sygnature as a leading player in the global drug discovery and pre-clinical CRO sector.
“They demonstrate our commitment to sustainable and secure growth of our company and continuing to broaden and enrich our in-house capabilities and therapeutic area expertise so that we are in an optimal position to serve our growing customer base.”